Evidence map›Paper›PMID 41967855›Full record

ReviewToxicological sciences : an official journal of the Society of Toxicology2026

Unveiling toxicological adverse outcomes: toward construction and simulation of large-scale networks.

Nensi Ikonomi, Natalie Ketter, Mario A A Pepe

Abstract readReview
In one paragraph

Review in Toxicological sciences : an official journal of the Society of Toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nensi IkonomiGlobal Non-clinical Safety Science, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach, 88397, Germany.
Natalie KetterGlobal Non-clinical Safety Science, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach, 88397, Germany.
Mario A A PepeGlobal Non-clinical Safety Science, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach, 88397, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting toxicological adverse outcomes is crucial for advancing in silico toxicology strategies. Modern toxicology increasingly relies on systems biology approaches to model and interpret these outcomes. Adverse outcome pathways (AOPs) focus on systems-level descriptions and causal linear relations among initiating, key, and adverse outcome events. Key characteristics (KC)-based topologies capture mechanistic breadth via interconnected property-based modules without assuming linear causality. From another perspective, emerging physiological maps dive deeper into toxicological mechanisms by mapping them at the detailed molecular level. To capture the dynamic nature of toxicological responses, especially their time- and dose-dependent behaviors, there is growing interest in integrating systems biology and mathematical modeling strategies. Although dynamic models have been applied to small-scale AOPs, larger regulatory networks remain largely unexplored from a dynamic perspective. In this review, we highlight recent efforts to combine systems and network biology approaches for predicting toxicological adverse outcomes, covering network construction, analysis, and dynamic predictions. We also explore the aspect of dynamically simulating large-scale molecular networks and its potential contribution to systems toxicology. Specifically, we charter the use of logic-based models (Boolean networks) as an integrative approach to understand molecular crosstalk and cellular phenotypes, highlighting the potential repurpose of existing models. To this end, we show 2 use cases on toxicological applications of Boolean network models. Finally, we prospectively discuss the importance and need of bridging molecular and systemic scales and integrating these modeling strategies with high-dimensional data sources, including omics and multi-omics datasets.

Indexed as

Adverse Outcome PathwaysComputer SimulationModels, BiologicalSystems BiologyToxicologyAnimalsGene Regulatory NetworksHumansRisk Assessmentadverse outcome predictionBoolean networksdynamic simulationlarge-scale network modelsmolecular crosstalks

Identifiers

PMID41967855
PMCPMC13120877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.